Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SGA.0000000000000697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis.
Eur J Clin Microbiol Infect Dis
January 2025
University of Sassari, Sassari, Italy.
Introduction: Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections.
Methods: We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024.
[Clinical decision rules for chest pain in primary care are supported by weak evidence and are difficult to apply.].
Recenti Prog Med
January 2025
Department of General practice, University Hospital Würzburg, Germany.
Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0.
Clin Mol Hepatol
January 2025
Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, China.
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements.
View Article and Find Full Text PDFAssessing the effectiveness of the SOLIO Alfa Cure Plus device in treating low back pain: a randomized controlled study.
J Orthop Surg Res
January 2025
Institute for Pain Medicine, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Background: Nonspecific low back pain (LBP) has become a significant worldwide public health problem. It is estimated that 84% of people present it at some point in their lives, in which 23% experience its chronic form, negatively affecting their daily lives. Because pain management tool that doesn't require a firm diagnosis, the development of a device, as SOLIO Alfa Cure Plus, that emanates low level laser therapy, radio frequency and heat with the goal of easing chronic back pain was highly expected.
View Article and Find Full Text PDFApplication of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease.
Transl Neurodegener
January 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are diverse in clinical presentation and are caused by complex and multiple factors, including genetic mutations and environmental factors. Numerous therapeutic approaches have been developed based on the genetic causes and potential mechanisms of ALS and HD. Currently, available treatments for various neurodegenerative diseases can alleviate symptoms but do not provide a definitive cure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!